From Challenges to Solution: The Evolving Landscape of Leprosy Management

Author:

Moreira Lívia Maria Coelho de Carvalho1,Oliveira Antônia Carla de Jesus1,Chaves Luíse Lopes1,Soares Mônica Felts de La Rocca1,Soares‐Sobrinho José Lamartine1ORCID

Affiliation:

1. Department of Pharmaceutical Sciences Quality Control Center of Medicines and Correlasts—NCQMC, Federal University of Pernambuco Recife Pernambuco 50740‐520 Brazil

Abstract

AbstractLeprosy, caused by Mycobacterium leprae, despite being a curable disease when treated can induce peripheral neuropathy. However, the medicines used in polychemotherapy promote several side effects. Thus, research for the development of new administration systems is an alternative, but there is a lack of preclinical and clinical studies of the systems, where 90.90% have a level of technological maturity 3 and 9.09% level 4. The main issues are associated with deficiencies in vitro and in vivo cultivation methodologies, lack of financing, as well as the disinterest of the pharmaceutical industry in investing in neglected tropical diseases. In addition, with the emergence of resistant bacteria, there is urgency in the search for vaccines and, therefore, in the expansion of immunomodulation studies to define the molecular targets of the vaccine and future medications. In addition, future treatments for various diseases, including leprosy, will be directly influenced by the evolution of additive manufacturing and 3D printing, seeking personalized, flexible, and reproducible treatment.

Publisher

Wiley

Reference121 articles.

1. Advances in the pathogenic, genetic and immunological studies of leprosy

2. Drug resistance in leprosy: An update following 70 years of chemotherapy

3. Treatment and Evaluation Advances in Leprosy Neuropathy

4. Gene Expression Profile of Mycobacterium leprae Contribution in the Pathology of Leprosy Neuropathy

5. World Health Organization (WHO) Global leprosy ( Hansen disease ) update 2021: Moving towards interruption of transmission2022 36 429 Available at :https://iris.who.int/bitstream/handle/10665/362412/WER9736‐429‐450‐eng‐fre.pdf?sequence=1

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3